

DAFTAR PUSTAKA

1. KDIGO. (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
2. Rasyid, H. (2021). Perhimpunan Nefrologi Indonesia Konsensus Nutrisi Pada Penyakit Ginjal Kronik.
3. Nutritional and Dietary Management of Chronic Kidney Disease Under Conservative and Preservative Kidney Care Without Dialysis. Rhee, Connie M. et al. *Journal of Renal Nutrition*, Volume 33, Issue 6, S56 - S66.
4. Pernefri. 2019. Konsensus Nutrisi Pada Penyakit Ginjal Kronik. Perhimpunan Nefrologi Indonesia. Jakarta: Pernefri.
5. Sakaguchi Y, Kaimori JY, Isaka Y. Plant-Dominant Low Protein Diet: A Potential Alternative Dietary Practice for Patients with Chronic Kidney Disease. *Nutrients*. 2023 Feb 16;15(4):1002.
6. Ko GJ, Obi Y, Tortorici AR, Kalantar-Zadeh K. Dietary protein intake and chronic kidney disease. *Curr Opin Clin Nutr Metab Care* 2017;20:77–85.
7. Bellizzi V, Carrera JJ, Chauveau P, et al. Retarding Chronic Kidney Disease (CKD) Progression: A Practical Nutritional Approach for Non-Dialysis CKD. *Nephrology @ Point of Care*. 2016;2(1).
8. Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. *Cochrane Database Syst Rev*. 2020;10:CD001892.
9. Shen Y, Fan N, Ma SX, Cheng X, Yang X, Wang G. Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy. *MedComm* (2020). 2025 Apr 18;6(5):e70168. doi: 10.1002/mco2.70168.
10. Liu J. R., Miao H., Deng D. Q., Vaziri N. D., Li P., and Zhao Y. Y., “Gut Microbiota-derived Tryptophan Metabolism Mediates Renal Fibrosis by Aryl Hydrocarbon Receptor Signaling Activation,” *Cellular and Molecular Life Sciences* 78, no. 3 (2021): 909–922.
11. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D. Gut microbiome in chronic disease: challenges and opportunities. *Transl Res* [Internet]. May);24–37.
Wada T. Gut microbiota and chronic kidney disease. *Japanese J Nephrol* 2017;59(4):545–51.



13. Peters, B. A., Qi, Q., Usyk, M., Daviglius, M. L., Cai, J., Franceschini, N., Lash, J. P., Gellman, M. D., Yu, B., Boerwinkle, E., Knight, R., Burk, R. D., & Kaplan, R. C. (2023). Association of the gut microbiome with kidney function and damage in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). *Gut microbes*, 15(1), 2186685.
14. Ramezani, A., & Raj, D. S. (2014). The gut microbiome, kidney disease, and targeted interventions. *Journal of the American Society of Nephrology : JASN*, 25(4), 657–670.
15. Rysz J, Franczyk B, Lawisnki J, Olszeweski R, Cialkowska-Rysz A, Gluba-Brzozka A. Uremic toxin levels are associated with gut microbiome changes in kidney transplant recipients. *Transpl Int* [Internet]. 2021;34(SUPPL 1):231.
16. Gut E, Soulage O, Popkov VA, Zharikova AA, Demchenko EA, Andrianova N V, et al. Citation: Gut Microbiota as a Source of Uremic Toxins. *Toxins Int J Mol Sci* [Internet]. 2022;2022:483.
17. Ebrahim, Z., Proost, S., Tito, R. Y., Raes, J., Glorieux, G., Moosa, M. R., & Blaauw, R. (2022). The Effect of β -Glucan Prebiotic on Kidney Function, Uremic Toxins and Gut Microbiome in Stage 3 to 5 Chronic Kidney Disease (CKD) Predialysis Participants: A Randomized Controlled Trial. *Nutrients*, 14(4), 805. <https://doi.org/10.3390/nu14040805>
18. Farnam Nia, S., Nasri, H., Mazaheri Tehrani, S., & Rouzbahani, S. (2024). Ameliorating impact of berberine on gut microbiota in chronic kidney disease. *Journal of Renal Endocrinology*. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D. Gut microbiome in chronic kidney disease: challenges and opportunities. *Transl Res* 2017;179:24–37.
19. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D. Gut microbiome in chronic kidney disease: challenges and opportunities. *Transl Res* 2017;179:24–37.
20. Corte-Iglesias V, Saiz ML, Andrade-Lopez AC, Salazar N, Bernet CR, Martin-Martin C, et al. Propionate and butyrate counteract renal damage and progression to chronic kidney disease. *Nephrol Dial Transplant*. 2025;40:133-150.
21. Huang W, Man Y, Gao C, Zhou L, Gu J, Xu H, et al. Short-Chain Fatty Acids Ameliorate Diabetic Nephropathy via GPR43-Mediated Inhibition of Oxidative Stress β Signaling. *Oxid Med Cell Longev*. 2020;4074832.
- su C-N, Lin I, Lo M, Yang M-Y, Tain Y. The Association Between Changes Short-Chain Fatty Acid Concentrations and Hypertension in Children With Kidney Disease. *Front Pediatr*. 2021;8:613641



23. Sun Y, Zhou C, Chen Y, He X, Gao F, Xue D. Quantitative increase in short-chain fatty acids, especially butyrate protects kidney from ischemia/reperfusion injury. *J Investig Med*. 2021;70:29-35.
24. Li Y, Ma J, Loh Y, Chadban S, Wu H. Short-chain fatty acids directly exert anti-inflammatory responses in podocytes and tubular epithelial cells exposed to high glucose. *Front Cell Dev Biol*. 2023;11:1182570.
25. Onyszkiewicz M, Gawrys-Kopczynska M, Sałagaj M, Aleksandrowicz M, Sawicka A, Koźniewska E, et al. Valeric acid lowers arterial blood pressure in rats. *Eur J Pharmacol* 2020;877:173086.
26. Chen L, He F, Dong Y, Huang Y, Wang C, Harshfield G, et al. Modest Sodium Reduction Increases Circulating Short-Chain Fatty Acids in Untreated Hypertensives. *Hypertension*. 2020;76:73-79.
27. Watanabe, S., Adachi, K., Wakino, S., Hisada, T., & Mochizuki, J. (2022). Dietary therapy with low protein genmai (brown rice) to improve the gut-kidney axis and reduce CKD progression. *Asia Pacific journal of clinical nutrition*, 31(3), 341–347.
28. Wang, P., Zhang, X., Zheng, X., Gao, J., Shang, M., Xu, J., & Liang, H. (2022). Folic Acid Protects against Hyperuricemia in C57BL/6J Mice via Ameliorating Gut-Kidney Axis Dysfunction. *Journal of agricultural and food chemistry*, 70(50), 15787–15803.

